NCT05938270CompletedPhase 1
A trial to examine the biological effects of Saruparib (AZD5305) alone, Darolutamide alone, and in combination in patients with newly diagnosed prostate cancer due to have radical prostatectomy.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 3 Jun 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- First submitted
- 20 Jun 2023
- Start date
- 11 Dec 2023
- Lead sponsor
- AstraZeneca AB
- Diseases
- Prostate cancer
- EU CT number
- 2023-503691-25-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 44
- 6 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Hospital Clinic de Barcelona Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Hospital Universitario 12 de Octubre Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Fundación Instituto Valenciano de Oncología Coordinator of this site? Confirm its status | Valencia | Spain | Completed |
| Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Completed |
| Stichting Radboud University Medical Center Coordinator of this site? Confirm its status | Nijmegen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.